A randomized trial evaluating a predominantly fetal growth-based strategy to guide management of gestational diabetes in Caucasian women
- PMID: 14747203
- DOI: 10.2337/diacare.27.2.297
A randomized trial evaluating a predominantly fetal growth-based strategy to guide management of gestational diabetes in Caucasian women
Abstract
Objective: To compare the management of Caucasian women with gestational diabetes (GDM) based predominantly on monthly fetal growth ultrasound examinations with an approach based solely on maternal glycemia.
Research design and methods: Women with GDM who attained fasting capillary glucose (FCG) <120 mg/dl and 2-h postprandial capillary glucose (2h-CG) <200 mg/dl after 1 week of diet were randomized to management based on maternal glycemia alone (standard) or glycemia plus ultrasound. In the standard group, insulin was initiated if FCG was repeatedly >90 mg/dl or 2h-CG was >120 mg/dl. In the ultrasound group, thresholds were 120 and 200 mg/dl, respectively, or a fetal abdominal circumference >75th percentile (AC>p75). Outcome criteria were rates of C-section, small-for-gestational-age (SGA) or large-for-gestational-age (LGA) infants, neonatal hypoglycemia (<40 mg/dl), and neonatal care admission.
Results: Maternal characteristics and fetal AC>p75 (36.0 vs. 38.4%) at entry did not differ between the standard (n = 100) and ultrasound groups (n = 99). Assignment to (30.0 vs. 40.4%) and mean duration of insulin treatment (8.3 vs. 8.1 weeks) did not differ between groups. In the ultrasound group, AC>p75 was the sole indication for insulin. The ultrasound-based strategy, as compared with the maternal glycemia-only strategy, resulted in a different treatment assignment in 34% of women. Rates of C-section (19.0 vs. 18.2%), LGA (10.0 vs. 12.1%), SGA (13.0 vs. 12.1%), hypoglycemia (16.0 vs. 17.0%), and admission (15.0 vs. 14.1%) did not differ significantly.
Conclusions: GDM management based on fetal growth combined with high glycemic criteria provides outcomes equivalent to management based on strict glycemic criteria alone. Inclusion of fetal growth might provide the opportunity to reduce glucose testing in low-risk pregnancies.
Comment in
-
Never say never in medicine: confessions of an old dog.Diabetes Care. 2004 Feb;27(2):610-2. doi: 10.2337/diacare.27.2.610. Diabetes Care. 2004. PMID: 14747247 No abstract available.
-
A randomized trial evaluating a predominantly fetal growth-based strategy to guide management of gestational diabetes in caucasian women: response to Schaefer-Graf et al.Diabetes Care. 2004 Jul;27(7):1848; author reply 1848-9. doi: 10.2337/diacare.27.7.1848. Diabetes Care. 2004. PMID: 15220290 No abstract available.
-
Randomized trial evaluating a predominately fetal growth-based strategy to guide management of gestational diabetes in caucasian women: response to Schaefer-Graf et al.Diabetes Care. 2004 Aug;27(8):2090-1; author reply 2091-2. doi: 10.2337/diacare.27.8.2090. Diabetes Care. 2004. PMID: 15277454 No abstract available.
Similar articles
-
A randomized controlled trial using glycemic plus fetal ultrasound parameters versus glycemic parameters to determine insulin therapy in gestational diabetes with fasting hyperglycemia.Diabetes Care. 2001 Nov;24(11):1904-10. doi: 10.2337/diacare.24.11.1904. Diabetes Care. 2001. PMID: 11679455 Clinical Trial.
-
Use of fetal ultrasound to select metabolic therapy for pregnancies complicated by mild gestational diabetes.Diabetes Care. 1994 Apr;17(4):275-83. doi: 10.2337/diacare.17.4.275. Diabetes Care. 1994. PMID: 8026282 Clinical Trial.
-
Flexible treatment of gestational diabetes modulated on ultrasound evaluation of intrauterine growth: a controlled randomized clinical trial.Diabetes Metab. 2004 Jun;30(3):237-44. doi: 10.1016/s1262-3636(07)70114-3. Diabetes Metab. 2004. PMID: 15223975 Clinical Trial.
-
[Gestational diabetes mellitus (Update 2019)].Wien Klin Wochenschr. 2019 May;131(Suppl 1):91-102. doi: 10.1007/s00508-018-1419-8. Wien Klin Wochenschr. 2019. PMID: 30980150 Review. German.
-
[Gestational diabetes mellitus].Wien Klin Wochenschr. 2016 Apr;128 Suppl 2:S103-12. doi: 10.1007/s00508-015-0941-1. Wien Klin Wochenschr. 2016. PMID: 27052232 Review. German.
Cited by
-
Fetal biometry for guiding the medical management of women with gestational diabetes mellitus for improving maternal and perinatal health.Cochrane Database Syst Rev. 2019 Sep 3;9(9):CD012544. doi: 10.1002/14651858.CD012544.pub2. Cochrane Database Syst Rev. 2019. PMID: 31476798 Free PMC article.
-
The interdependence of mid-trimester blood pressure and glucose levels in shaping fetal growth and neonatal outcomes: implications for risk-benefit assessment and co-management.BMC Med. 2025 Mar 14;23(1):161. doi: 10.1186/s12916-025-03990-7. BMC Med. 2025. PMID: 40087732 Free PMC article.
-
The Relevance of Fetal Abdominal Subcutaneous Tissue Recording in Predicting Perinatal Outcome of GDM Pregnancies: A Retrospective Study.J Clin Med. 2020 Oct 21;9(10):3375. doi: 10.3390/jcm9103375. J Clin Med. 2020. PMID: 33096839 Free PMC article.
-
How many sonograms are needed to reliably predict the absence of fetal overgrowth in gestational diabetes mellitus pregnancies?Diabetes Care. 2011 Jan;34(1):39-43. doi: 10.2337/dc10-0415. Epub 2010 Sep 23. Diabetes Care. 2011. PMID: 20864517 Free PMC article.
-
Flexible treatment of gestational diabetes mellitus adjusted according to intrauterine fetal growth versus treatment according to strict maternal glycemic parameters: a randomized clinical trial.BMJ Open Diabetes Res Care. 2022 Dec;10(6):e002915. doi: 10.1136/bmjdrc-2022-002915. BMJ Open Diabetes Res Care. 2022. PMID: 36593648 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials